Skip to content

Retrospective Analysis of capsaïcin Patch in Complex Regional Pain Syndrome

Capsaïcin patch8% in Adult Complex Regional Pain Syndromes: a Retrospective Analysis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05523934
Enrollment
50
Registered
2022-09-01
Start date
2022-09-16
Completion date
2023-10-30
Last updated
2023-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex Regional Pain Syndromes

Brief summary

Complex regional pain syndrome is a painful syndrome often secondary to a traumatic lesion. Treatment is difficult, of long duration with variable outcomes. Patch of capsaïcin has been proposed as adjuvant to a multimodal treatment. Capsaïcin may act by its effect on transient receptor potential vanilloid 1. Efficacity and outcome studies with this treatment are lacking. The aim of this retrospective study is to evaluate pain intensity over time assessed by visual analog scale in patient with complex regional pain syndrome treated with capsaïcin patch in addition to their usual treatment.

Interventions

DRUGCapsaïcine patch

Patients with complex regional pain syndrome under maximal conventional treatment having a supplementary treatment by a capsaïcin patch.

Sponsors

Brugmann University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Adult patients with complex regional pain syndrome on maximum medical treatment * Age ≥18 years * Patients treated between 2012 and August 31, 2022 in the pain clinic of the CHU Brugmann

Exclusion criteria

\- incomplete medical chart

Design outcomes

Primary

MeasureTime frameDescription
Pain intensity3 month periodPain intensity evaluated by a visual analog scale (on a scale 0 to 10) by patients before and after capsaïcin addition.

Countries

Belgium

Contacts

Primary ContactDenis Schmartz, MD
denis.schmartz@chu-brugmann.be+3224773996
Backup ContactCharlie Reynaud, MD
Charlie.REYNAUD@chu-brugmann.be+3224773996

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026